Related Experiment Video
Updated: Dec 21, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
[Molecular docking study and experimental evaluation of potential CTLA-4 binding peptides]
S V Podlesnykh1, V V Lampatov2, A I Khlebnikov3
1Russian-American Anti-Cancer Center, Altai State University, Barnaul, Russia.
Abstract:
Current advances in research of immune checkpoints CTLA-4, PD-1, PD-L1, opened new possibilities for effective cancer immunotherapy using monoclonal antibodies. However, antibodies have a number of limitations for clinical use, which provides a basis for the search for low molecular weight compounds capable of regulating (blocking) molecules that inhibit the immune response. This paper presents the results of molecular docking and evaluation of synthetic peptide interaction with a CTLA-4 molecule. Using mathematical modeling, it was shown that peptides interacted with the 99MYPPPY104 loop of the CTLA-4 protein and could potentially block the interaction of the CTLA-4 receptor with its natural ligand B7-1. The specificity of the interaction between the identified peptide and recombinant chimeric CTLA-4 protein was evaluated. The detected synthetic peptide can be used for the development of immunomodulatory drugs for therapy of cancer or autoimmune diseases.
Insights
Researchers identified a synthetic peptide that interacts with the CTLA-4 molecule, potentially blocking immune suppression. This peptide could lead to new immunomodulatory drugs for cancer and autoimmune diseases.
Area of Science:
- Immunology
- Computational Chemistry
- Drug Discovery
Background:
- Immune checkpoints like CTLA-4, PD-1, and PD-L1 are targets for cancer immunotherapy.
- Monoclonal antibodies are effective but have clinical limitations.
- Low molecular weight compounds are sought to regulate immune response inhibitors.
Purpose of the Study:
- To investigate the interaction of synthetic peptides with the CTLA-4 molecule.
- To evaluate the potential of these peptides as alternatives to antibodies for immune regulation.
Main Methods:
- Molecular docking simulations were employed to predict peptide-CTLA-4 interactions.
- Mathematical modeling was used to analyze binding at the 99MYPPPY104 loop.
- Specificity was assessed using recombinant chimeric CTLA-4 protein.
Main Results:
- Synthetic peptides were found to interact with the 99MYPPPY104 loop of CTLA-4.
- These peptides demonstrated potential to block the CTLA-4 receptor's interaction with its ligand, B7-1.
- The specificity of peptide interaction with CTLA-4 was confirmed.
Conclusions:
- A synthetic peptide was identified with the potential to modulate CTLA-4 activity.
- This peptide may serve as a basis for developing novel immunomodulatory drugs.
- Potential therapeutic applications include cancer and autoimmune disease treatment.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024